Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 202Carcinoma, Renal Cell 68Liver Neoplasms 61Neoplasms 53Neoplasm Metastasis 34Leukemia, Myeloid, Acute 34Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 29Melanoma 24Kidney Neoplasms 21Pancreatic Neoplasms 16Brain Neoplasms 15Sarcoma 14Prostatic Neoplasms 14Lung Neoplasms 14Recurrence 13Glioblastoma 13Thyroid Neoplasms 11Colorectal Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Carcinoma 10Urinary Bladder Neoplasms 8Rectal Neoplasms 8Ovarian Neoplasms 8Myelodysplastic Syndromes 8Multiple Myeloma 8Gliosarcoma 8Stomach Neoplasms 7Colonic Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6

Interventions

Everolimus 10Octreotide 7pasireotide 5lanreotide 5gallium Ga 68 dotatate 4lutetium Lu 177 dotatate 3cabozantinib 3Sunitinib 3Nivolumab 3ganitumab 2Temozolomide 2Erlotinib Hydrochloride 2Capecitabine 2Bevacizumab 2zimberelimab 1veliparib 1telotristat ethyl 1surufatinib 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1olaparib 1nintedanib 1ibrutinib 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1carfilzomib 1azaspirane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoid Tumor × Sorafenib × Clear all
NCT00942682 2014-04-29

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
21 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡